Vanguard Capital Management
MTNB icon

Vanguard Capital Management’s Matinas BioPharma MTNB Stock Holding History

Vanguard Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Hold
40,110
– – ﹤0.01% 4001
2026
Q1 		$20.1K Buy
+40,110
New +$25.1K ﹤0.01% 3982

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's MTNB Position: Q2 2026 in Review

Vanguard Capital Management held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 40,110 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4001.

Vanguard Capital Management first reported a position in MTNB in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Vanguard Capital Management held 40,110 shares of Matinas BioPharma worth $24.5K as of Q2 2026.
  • Vanguard Capital Management left its Matinas BioPharma share count unchanged in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4001 holding.
  • Vanguard Capital Management first reported a position in Matinas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.